• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Quest Diagnostics to Contribute Biomarker Datasets to Support One Brave Idea Initiative

by Fred Pennic 08/07/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Quest Diagnostics to Contribute Biomarker Datasets to Support One Brave Idea Initiative

In a move to advance the ground-breaking work to identify coronary heart disease at the earliest transition from wellness to disease, Quest Diagnostics announced it will contribute biomarker implementation, population health analytics and a national lab platform as a pillar supporter of One Brave Idea, the research initiative co-founded by the American Heart Association (AHA) and Verily Life Sciences with significant support from AstraZeneca.

The Burden of Cardiovascular Disease

Heart disease is the number 1 killer worldwide.  Stroke ranks second globally and is the leading cause of severe disability. An estimated 17.7 million people die from cardiovascular disease annually, representing 31 percent of all global deaths.  Precision medicine offers the promise of better patient outcomes through earlier prediction of disease and targeted treatments for individuals.

One Brave Idea Research Initiative Overview

One Brave Idea was established to pursue unconventional scientific approaches in order to make major advances in the fight against coronary heart disease. The research initiative led by Dr. Calum MacRae, vice chair for Scientific Innovation in the department of Medicine at Brigham and Women’s Hospital.

The One Brave Idea Team comprises a group of leading scientists from multiple disciplines working together to understand the earliest stages of coronary heart disease (CHD). One Brave Idea is working to create a coronary heart disease early warning system by investigating what happens 10-20 years before any risk factors typically appear. A key aim is to develop novel diagnostic techniques to identify cardiovascular disease, including stroke, in stages where discreet forms can be identified, and preventive measures initiated to stop or reverse disease progression.

Consumers are more engaged in their health than ever before and healthcare innovation is happening at every corner, opening up a whole new world for evidence-based diagnostics that can be broadly scaled across hospitals and clinics for real-world implementation.

Quest Diagnostics Deep Biomarker Expertise

Quest Diagnostics will provide state-of-the-art diagnostic services and population health analytics in support of OBI research. Through its Cleveland HeartLab, Quest Diagnostics maintains a pipeline of early-stage genetic and biological markers in cardiometabolic disorders with the potential for future diagnostic services for clinical use and pharmaceutical research.

Additionally, Quest Diagnostics deep biomarker expertise and rich dataset of de-identified laboratory testing on millions of patients for cardiovascular, metabolic and other disorders is expected to inform OBI research. Quest Diagnostics also maintains avenues to directly engage patients and providers, a common impediment to scale research. These avenues include Quest Quanum™ connectivity to about half the physicians in the United States, a network of 2,200 patient service centers, and the myQuest™ patient app, which has six million subscribers.

Why It Matters

“We share the commitment of One Brave Idea and its member organizations and scientists in establishing the path to heart disease prevention,” said Steve Rusckowski, chairman, president and CEO for Quest Diagnostics and a member of the American Heart Association CEO Roundtable. “For far too many people, the first sign of heart disease is a fatal event, such as a myocardial infarction (heart attack) or stroke. Our collaboration in One Brave Idea aims to change that. Quest Diagnostics brings robust biomarker and medical expertise, population health analytics and national presence to accelerate discovery of early disease biomarkers and biology changes and fast-track prevention measures that can create a healthier world.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: American Heart Association, AstraZeneca, Biomarker-Guided Drug Development, Biomarkers, Cleveland HeartLab, dataset, healthcare innovation, Heart, heart disease, Life Sciences, One Brave Idea, physicians, Population Health, Population Health Analytics, Precision Medicine, Quest Diagnostics, risk, Verily

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

'Cranky Index' Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

‘Cranky Index’ Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Chipiron Secures $17M to Transform MRI Access with Portable Scanner

Chipiron Secures $17M to Transform MRI Access with Portable Scanner

Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR

Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |